Vaxcyte premarket shares surge after vaccine meets late-stage trial goals
In short
Vaxcyte's pneumococcal vaccine reached the goals of a late-stage clinical trial, and the US-listed company's shares rose sharply in premarket trading on 5 October, according to CLS, Yicai and Jiemian. CLS reported premarket gains of more than 25%, then more than 61%, then more than 85% during the afternoon, while Yicai reported more than 73% and Jiemian published two items citing more than 25% and more than 85%. At the US market open, CLS and Jiemian reported Vaxcyte up more than 54% while the three main indices opened mixed.
Read the full story 1 min read
Vaxcyte shares rose sharply in US premarket trading on 5 October after the company's pneumococcal vaccine reached the goals of a late-stage clinical trial, according to reports from CLS, Yicai and Jiemian. CLS reported the premarket gain at more than 25% at 18:13 local time, more than 61% at 18:26 and more than 85% at 18:35. Yicai reported a gain of more than 73% at 18:40, and Jiemian published two items at 18:52, one citing a gain of more than 25% and another more than 85%. None of the reports explained the differing figures. [ 1 , 2 , 3 , 4 , 5 , 6 ]
When the US market opened at 21:30 local time, CLS reported Vaxcyte up more than 54% and the three main US indices opening mixed: the Dow Jones Industrial Average down 0.14%, the S&P 500 up 0.08% and the Nasdaq Composite up 0.15%. Jiemian carried the same figures at 21:52. [ 7 , 8 ]
The same market reports listed other movers: Critical Metals rose more than 8% after Greenland approved the mining and mine-closure plan for its Tanbreez project; Vistra Energy rose more than 3% after the United States was to provide it with a $4 billion loan to increase nuclear power generation; and cryptocurrency-related stocks Circle, Coinbase and Strategy each rose more than 2%. [ 7 , 8 ]
The documents did not give details of the trial, such as which endpoints were measured, how many participants were involved or when the data were released; the vaccine was described only as having met late-stage clinical trial goals, and no company statement was included. [ 1 , 2 , 3 , 5 , 6 , 7 , 8 ]
Why it matters
The reports show how sharply a biotech developer's valuation can move on late-stage trial data, and the vaccine programme itself concerns a pneumococcal vaccine, a product category of wide public-health interest. The documents give no trial details, no company comment and no explanation of the differing premarket figures, so the significance of the result itself cannot be assessed from this coverage.
Key facts
- CLS, Yicai and Jiemian reported that Vaxcyte's pneumococcal vaccine reached the goals of a late-stage clinical trial. [ 1 , 2 , 3 , 5 , 6 , 7 , 8 ]
- CLS reported the Vaxcyte premarket gain at more than 25% at 18:13 local time, more than 61% at 18:26 and more than 85% at 18:35. [ 1 , 2 , 3 ]
- Yicai reported a Vaxcyte premarket gain of more than 73% at 18:40 local time. [ 4 ]
- Jiemian published two items at 18:52 local time, one citing a premarket gain of more than 25% and the other more than 85%. [ 5 , 6 ]
- At the US market open at 21:30 local time, CLS reported Vaxcyte up more than 54%, with the Dow down 0.14%, the S&P 500 up 0.08% and the Nasdaq Composite up 0.15%. [ 7 , 8 ]
- The same market reports said Critical Metals rose more than 8% after Greenland approved the mining and closure plan for its Tanbreez project, and Vistra Energy rose more than 3% after the United States was to provide a $4 billion loan to increase nuclear generation. [ 7 , 8 ]
- Cryptocurrency-related shares Circle, Coinbase and Strategy each rose more than 2%, according to the same reports. [ 7 , 8 ]
Confirmed by several sources
- Vaxcyte's pneumococcal vaccine reached late-stage clinical trial goals, according to CLS, Yicai and Jiemian. [ 1 , 2 , 3 , 5 , 6 , 7 , 8 ]
- Vaxcyte shares rose in premarket trading on 5 October, as reported by CLS, Yicai and Jiemian. [ 1 , 2 , 3 , 4 , 5 , 6 ]
- US stocks opened mixed, with Vaxcyte up more than 54%, according to CLS and Jiemian. [ 7 , 8 ]
Still unclear
- The exact size of Vaxcyte's premarket gain The figures differ across reports, ranging from more than 25% to more than 85%, and Jiemian published two different figures at the same publication time without explaining the difference.
- What the late-stage trial measured, how many participants it involved or whether all endpoints were met The documents state only that the vaccine reached late-stage clinical trial goals and give no trial data.
- Whether Vaxcyte or the trial investigators commented No company statement, executive or investigator is quoted in any of the documents.
What local media are saying
Timeline, local time
- CLS reports Vaxcyte up more than 25% in US premarket trading after its pneumococcal vaccine reached late-stage clinical trial goals. [ 1 ]
- CLS updates the premarket gain to more than 61%. [ 2 ]
- CLS updates the premarket gain to more than 85%. [ 3 ]
- Yicai reports a premarket gain of more than 73%. [ 4 ]
- Jiemian publishes two items, citing premarket gains of more than 25% and more than 85%. [ 5 , 6 ]
- US markets open: CLS reports Vaxcyte up more than 54%, the Dow down 0.14%, the S&P 500 up 0.08% and the Nasdaq Composite up 0.15%. [ 7 ]
- Jiemian carries the same market-open figures, including Vaxcyte up more than 54%. [ 8 ]